Clinical trial
A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
NCT03227471 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 23, 2017
- Completion date
- March 27, 2018
- Enrollment
- 225 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.